Parkwalk have been named in the ‘top 10 most active investors’ in Beauhurst’s annual report on equity investment in the UK private markets – The Deal 2021. To download the full report click here.

The report highlights some key findings in private market fundraising, including a 17% increase in deal volume, and 100% increase in deal value from 2020.

It also sheds light on flourishing sectors such as cleantech and life sciences, despite fintech remaining the dominant high-growth sector in 2021. Both life sciences and cleantech are sectors that Parkwalk invests in heavily in as part of our core investment strategy focused on university spin-outs, with our portfolio including companies such as hydrogen fuel cell stack developer Bramble Energy, photovoltaics company Oxford PV, Xampla who produce a plant-protein based natural alternative to plastic and Cheesecake Energy, a green energy storage technology company. On the life sciences side, some of our biggest funding rounds that we participated in 2021 include PetMedix, an animal therapeutics company as part of a $37m Series B round, and Mogrify, a cell therapeutics company as part of a $17m Series A round. A final point to note in the report is that AI in the life sciences space is picked out as a key area to watch in 2022. It is an area in which Parkwalk is already active, with recent investments into companies such as Brainomix, which has pioneered the development of an AI platform improving treatment and diagnosis of conditions such as a stroke.

To find out more about Parkwalk’s investment strategy click here.

To download the full Beauhurst Deal 2021 report click here.